Inovio's New Website - GeneSwitch.com - Supports Novel Gene Expression Technology.

Medical Research Tool Being Used by GlaxoSmithKline, Wyeth and Bayer Available for Licensing

SAN DIEGO -- Inovio Biomedical Corporation (AMEX:INO), which is focused on the development of DNA vaccines and a novel solid tumor ablation therapy, announced today it has launched the website www.GeneSwitch.com to provide extensive technical information on Inovio's gene regulation technology that allows researchers to regulate, via administration of an orally available compound, the intensity and duration of gene expression from genes delivered to cells or animals.

The GeneSwitch([R]) gene regulation technology is currently licensed for research purposes to Bayer Schering Pharma AG, GlaxoSmithKline, Organon, Senomyx, Wyeth, and Genzyme and is available in a kit form for academic research from Invitrogen.

"The GeneSwitch([R]) regulation system used in combination with the efficient transfection observed using our proprietary electroporation technology is an attractive and convenient way to achieve gene delivery and then control resulting gene expression," noted Avtar Dhillon, president and CEO of Inovio. "This total solution would be particularly useful for research purposes and could potentially be used to treat protein deficiency diseases such as anemia, which results from erythropoietin (EPO) deficiency, and hemophilia, which results from factor IX deficiency."

About Inovio Biomedical Corporation

Inovio Biomedical Corporation is focused on commercializing its Selective Electrochemical Tumor Ablation (SECTA) therapy and development of multiple DNA vaccines using its delivery platform for gene-based treatments. SECTA is a local ablation therapy for solid tumors that is designed to selectively kill cancerous cells and minimize cosmetic or functional impacts to predominantly healthy tissue typically treated around the tumor. Inovio is moving its lead product, the MedPulser[R], through pre-marketing studies for head and neck cancer and skin cancers in Europe, where it has CE Mark accreditation, a U.S. phase III pivotal study for head and neck cancer, and a phase I/II trial for breast cancer. Inovio's DNA delivery partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, and the U.S. Army, with four gene-based therapies and DNA vaccines in phase I clinical studies. Inovio is a leader in developing human therapeutic applications of electroporation, which uses brief, controlled electrical pulses to dramatically increase cellular uptake of a useful biopharmaceutical, with the industry's most extensive patent portfolio covering in vivo electroporation. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our plans to develop our electroporation drug and gene delivery technology and about the availability of supporting Internet technology. Actual events or results may differ from our expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs (including, but not limited to, the fact that pre-clinical results referenced in this release may not be indicative of results achievable from testing in humans), the effectiveness of the new website, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of Inovio's technology as a delivery mechanism, the availability or potential availability of alternative therapies or treatments for the conditions targeted by Inovio or its collaborators , including alternatives that may be more efficacious or cost-effective than any therapy or treatment that Inovio and its collaborators hope to develop, evaluation of potential opportunities, issues involving patents and whether they or licenses to them will provide Inovio with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether Inovio can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, and other factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2005, our Form 10-Q for the nine months ended September 30, 2006, and other regulatory filings. There can be no assurance that any product in our product pipeline will be successfully developed or manufactured, or that final results of clinical studies will be supportive of regulatory approvals required to market licensed products.